PHK
CLDX icon

Point72 Hong Kong’s Celldex Therapeutics CLDX Stock Holding History

Point72 Hong Kong’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,559
Closed -$107K – 487
2024
Q1 		$107K Buy
+2,559
New +$105K 0.01% 425
2022
Q2 		– Sell
-1,394
Closed -$47K – 1972
2022
Q1 		$47K Buy
1,394
+511
+58% +$16.3K ﹤0.01% 1347
2021
Q4 		$34K Sell
883
-2,337
-73% -$102K ﹤0.01% 1431
2021
Q3 		$174K Buy
+3,220
New +$151K 0.01% 1206
2018
Q3 		– Sell
-812
Closed -$6K – 929
2018
Q2 		$6K Buy
812
+776
+2,156% +$10.4K ﹤0.01% 692
2018
Q1 		$1K Buy
+36
New +$1.4K ﹤0.01% 822
2017
Q4 		– Sell
-36
Closed -$2K – 875
2017
Q3 		$2K Buy
+36
New +$1.35K ﹤0.01% 641
2017
Q1 		– Sell
-36
Closed -$2K – 758
2016
Q4 		$2K Buy
+36
New +$2.05K ﹤0.01% 770

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Hong Kong's CLDX Position: Q2 2024 in Review

Point72 Hong Kong sold out of Celldex Therapeutics (CLDX) in Q2 2024, closing a stake of 2,559 shares — an estimated $107K sold.

Point72 Hong Kong first reported a position in CLDX in Q4 2016 and held it in 8 quarters. The position peaked at $174K in Q3 2021. 183 funds tracked by Wall St. Rank hold CLDX as of Q2 2024.

  • Point72 Hong Kong reported no remaining Celldex Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Point72 Hong Kong sold 2,559 Celldex Therapeutics shares in Q2 2024, an estimated $107K.
  • Point72 Hong Kong first reported a position in Celldex Therapeutics in Q4 2016 and held it in 8 quarters.
  • Point72 Hong Kong's Celldex Therapeutics position peaked at $174K in Q3 2021.
  • 183 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2024.

Based on Point72 Hong Kong's 13F filing for Q2 2024, filed 14 Aug 2024.